Advisory Council December 2013 Meeting Presentation: Research Progress Report

12/02/2013

ADVISORY COUNCIL ON ALZHEIMER'S RESEARCH, CARE, AND SERVICES

Monday, December 2, 2013

 

NAPA Research Progress Report

Richard J. Hodes, M.D.
Chair, Federal Research Subcommittee

Predicted Mechanisms of LOAD GWAS Alzheimer’s Disease Associated Genes

Innate immune/ brain inflammatory response Endocytosis and cellular protein trafficking including APP trafficking Lipid transport/ metabolism Synaptic transmission Cytoskeletal function
HLA-DRB5/HLA-DRB1
TREM2
CR1
CLU
MS4A4/MS4A6E
EPHA1
INPP5D
ABCA7
SORL1
PICALM
BIN1
CD2AP
APOE
CLU
ABCA7
PTK2B
MEF2C
CELF1
NME8
CASS4
FERMT2
Nature Genetics (Oct. 27, 2013)

Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease

2013 RFA: Interdisciplinary Approach to Identification and Validation of Novel Therapeutic Targets for AD

  • Supports interdisciplinary and integrative research focused on identification and preclinical validation of novel targets for AD treatment and prevention
    • Encourages the pursuit of paradigm-shifting biological and therapeutic hypotheses and promotes the creation of new translational teams
    • Encourages the use of network-based approaches, such as systems biology and systems pharmacology to gain understanding of the molecular and physiological context within which potential therapeutic targets operate
  • U01-A Systems Approach to Targeting Innate Immunity in Alzheimer’s -- Dr. Todd Golde, University of Florida, and Colleagues
  • U01-Pathway Discovery, Validation and Compound Identification for Alzheimer’s Disease -- Drs. Philip De Jager, Brigham and Women's Hospital, Broad Institute, Harvard University, Boston, and David Bennett, Rush University Medical School, Chicago
  • U01-Integrative Biology Approach to Complexity of Alzheimer’s Disease -- Dr. Eric Schadt of Icahn School of Medicine at Mount Sinai, New York City, and Team of investigators

Identification and Validation of Novel Therapeutic Targets for Alzheimer's Disease, RFA-AG-13-013: http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-13-013.html

2013 RFA: Alzheimer's Disease Prevention Trials

  • Phase II or Phase III clinical trials testing pharmacological (small molecules and biologics) and non-pharmacological interventions, in cognitively normal individuals at-risk for AD (e.g., individuals at risk genetically, older adults positive for biomarker evidence of Alzheimer’s disease pathology) or in individuals with MCI using a combination of biomarkers (fluid and imaging) and cognitive measures as outcomes.
  • UF1 - The Alzheimer's Prevention Initiative APOE4 Trial -- Drs. Eric Reiman and Pierre Tariot, Banner Alzheimer’s Institute, Phoenix, and Co-investigators
  • U01 -- Stimulating the Innate Immune System to Prevent Alzheimer’s -- Dr. Ted Ashburn, Sanofi Aventis, Cambridge, Mass., in partnership with Baylor College of Medicine, Houston, Texas

Not supported from RFA, but part of FY 2013 AD Funds:

  • U01 -The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Trial -- Dr. Randall Bateman, Washington University, St. Louis, MO, and Co-investigators

AD Prevention Trials, RFA-AG-13-015: http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-13-015.htm

2013 RFA: Alzheimer's Disease Phase I Clinical Trials

  • Provide support for first-in-human studies for promising AD therapeutics.
  • Evaluate the metabolic and pharmacological actions of drugs, including biologics in humans.
  • UF1- Allopregnanolone Regenerative Therapeutic for MCI/Alzheimer’s: Dose Finding Phase 1 -- Drs. Roberta Brinton and Lon Schneider, University of Southern California, Los Angeles

AD Phase I Clinical Trials , RFA-AG-13-016: http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-13-016.htm

 

Alzheimer's Disease-Related Dementias: Research Challenges and Opportunities

Sponsored by the National Institute of Neurological Disorders and Stroke in cooperation with:

  • National Institute on Aging
  • Alliance for Aging Research, ACT-AD
  • Alzheimer's Association
  • Association for Frontotemporal Degeneration
  • USAgainst Alzheimer's

http://www.ninds.nih.gov/ADRelatedDementias2013

CONFERENCE

  • Goals
    • Each topic area presents rationale for prioritized research recommendations and timelines
    • Provoke discussion among group experts
    • Solicit feedback and opinions from audience
  • Outcomes
    • 567 registrants: 322 in-person, > 200 on-line
    • Lively 2-day public session with many comments
      • Culminated with “open mike” and review of all suggested revisions
    • Closed session to plan post-conference work

EXECUTIVE SUMMARY - Overall

  Topic Area   Focus Area
  (number of prioritized research recommendations)  
1. Multiple etiology dementias (MED) Differential Diagnosis (3) Epidemiology (3)
2. Health disparities (HD) Recruitment (4) Advancing Treatment and Prevention Strategies (4)
3. Lewy body dementias (LBD) 1. Establish longitudinal cohorts with common measures, culminating in autopsy studies. (2) 2. Discover disease mechanisms through brain mapping and genetics (2) 3. Development and validate biological and imaging biomarkers (2) 4. Model disease processes to develop potential symptomatic and disease modifying therapies (2)
4. Frontotemporal dementia and other tauopathies (FTD) Basic Science: Pathogenesis and Toxicity (4) Clinical Science: Discovery, tools, and cohorts (4)
5. Vascular contributions to ADRD - focus on small vessel disease and AD/vascular interactions (VAS) Basic Mechanisms and Experimental Models (3) Human-Based Studies (3)

EXECUTIVE SUMMARY – Overlap

  • Although ordering of priorities and timelines differed, several recs applied across ADRD (and AD)
    • Fundamental research to fill critical knowledge gaps
    • Training and education to ensure durable progress
    • Improved diagnostics
    • Optimized repositories
    • All recommendations within HD
    • Culmination of research in effective interventions

 

Alzheimer's Disease Summit: The Path to 2025

November 6 - 7, 2013
The New York Academy of Sciences
Presented by The New York Academy of Sciences, National Institute on Aging/NIH and the Global CEO Initiative on Alzheimer's Disease

  • Primary Goal: To convene leading industry, academic, and government stakeholders in discussions regarding how to prevent and effectively treat Alzheimer's by 2025:
    • Coordinating with governmental efforts to build research resources
    • Reengineering our current drug development and evaluation systems
    • Identifying innovative technologies and financing models
  • Outcome: To comprise a research agenda that will delineate the pathways needed to effectively treat and prevent Alzheimer's disease by 2025.

http://www.nyas.org/pathto2025

 

UK Hosts the First G8 Dementia Summit on December 11, 2013

  • Host: The Right Honorable Jeremy Hunt MP
  • Participating Countries:
    • Canada
    • France
    • Germany
    • Italy
    • Japan
    • Russia
    • USA
    • United Kingdom

https://www.gov.uk/government/news/uk-to-host-g8-dementia-summit

SAVE THE DATE

Alzheimer's Disease Research Summit 2015
February 9-11, 2015
National Institutes of Health
U.S. Department of Health & Human Services
Bethesda, MD


Return to

National Alzheimer's Project Act Home Page

Advisory Council on Alzheimer's Research, Care, and Services Page

Advisory Council on Alzheimer's Research, Care, and Services Meetings Page

Preview
Download

"Mtg10-Slides1.pdf" (pdf, 1.14Mb)

Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®